Expression and Function of Tetraspanins and Their Interacting Partners in B Cells

Tetraspanins are transmembrane proteins that modulate multiple diverse biological processes, including signal transduction, cell–cell communication, immunoregulation, tumorigenesis, cell adhesion, migration, and growth and differentiation. Here, we provide a systematic review of the involvement of tetraspanins and their partners in the regulation and function of B cells, including mechanisms associated with antigen presentation, antibody production, cytokine secretion, co-stimulator expression, and immunosuppression. Finally, we direct our focus to the signaling mechanisms, evolutionary conservation aspects, expression, and potential therapeutic strategies that could be based on tetraspanins and their interacting partners.


Structure and evolutionary Conservation of Tetraspanins
Tetraspanins belong to a protein family in which members contain intracellular N-and C-termini, two extracellular domains (EC1 and EC2), and specifically four transmembrane domains ( Figure 3A; 6,7). Each phylum has evolved its own particular tetraspanins with distinction in the variety and abundance in different species. Despite this, the chemical composition of tetraspanins is highly conserved among species with four or more cysteine residues in a highly conserved "CCG" motif in the EC2 domain (8). There are 33 tetraspanins found in humans (Tables 1 and 2) and most of them preserve the characteristics of the ancient sequence in domain EC2.

General interactions Among Tetraspanins and Their Partners
Tetraspanins act as scaffold proteins to anchor multiple proteinsincluding other tetraspanins, partners of tetraspanins, and other proteins-to one area of the cell membrane, and form a tetraspanin-enriched microdomain (TEM) or tetraspanins web (10,11). A recent study with super resolution microscopy provided a close view of TEM and demonstrated that TEM is composed of individual nanoclusters (<120 nm). There are no more than 10 CD53 molecules in a single tetraspanin cluster of CD53. The study also evaluated the distances between the individual clusters, including CD53, CD37, CD81, CD82, and the tetraspanin partners such as CD19 and major histocompatibility complex class II (MHC II) (12). Based on the sensitivity and stringency to different detergents, the interactions of tetraspanins and partners in TEM were classified into three categories (13,14).
This model allows for dynamic and adaptable interactions between tetraspanins and other surface proteins based on a descriptive categorization without correlation to functionality in the living cell. A recent review proposed a new applaudable classification of tetraspanin interactions based on their function in the formation of TEM: interactions (a) necessary to maintain tetraspanin structure, (b) that support tetraspanin web formation, (c) that add functional partners to the web, and (d) that facilitate intracellular events (6). Three hypothetical models could be postulated to decipher the ways that tetraspanin microdomains enhance or regulate cellular signals and exert effects on fundamental biological processes. One model is that tetraspanins be considered a transmem brane linker connecting and augmenting signal transduction between membrane partners and intracellular-signaling proteins (15). Another model could propose that tetraspanins are involved in gathering partner membrane proteins which subsequently result in increased avidity and/or enhanced interaction with their ligands (16). The third hypothesis is that tetraspanins function as regulators by sequestering partners from signal transduction (17) thus preventing inappropriate signals and responses in resting cells. Without favoring any of these models at the present time, we now direct our attention to signal transduction and/or regulation by tetraspanins in immune cells ( Figure 3B).

Function of Tetraspanin/integrin Complexes in Signaling Pathway for Cell Migration and Adhesion
Tetraspanins associating with and forming tetraspanin/kinaseintegrin complexes are implicated in both leukocyte and cell-cell adhesion ( Figure 3B2) by causing signal activation and cytoskeletal reorganization. In B cells, by enhancing tyrosine phosphorylation levels, tetraspanin CD9 promotes β1 integrin-dependent mobility (23). In addition, tetraspanins CD9 as well as CD63, CD81 have been documented to associate with both PI4-kinase and integrin α3β1 in lymphoid cell lines (24). Finally, tetraspanins also have been found to enhance the avidity of integrins for neutrophil motility and T cell-B cell contact (25).

Function of Tetraspanin CD37 and its Partners in T Cell-B Cell Contact (TCR) Activation Pathway
Tetraspanins are implicated in TCR-induced activation and proliferation ( Figure 3B3). Interaction of peptide with the MHC activates the TCR and initiates the downstream signaling cascade of Src kinases Fyn and Lck. Lck subsequently activates the functional proteins involved in T cell activation and proliferation.
Interaction of Lck with CD4/CD8 plays crucial roles in this pathway (20); should CD4 associate with tetraspanins CD81/82 then Lck is sequestered from the TCR signaling pathway (26). Additional evidence shows that tetraspanin CD37 is coupled to TCR signal transduction mostly by influencing the dynamics of CD4-Lck distribution to TCR signal associated microdomains (27). Thus, tetraspanins regulate the T cell biologic process by influencing the TCR-CD4/CD8 cascade proximal to Lck mobilization.

Functions of Tetraspanins and Their Partners in Antigen-Presenting Processes
MHC avidity and facilitation of T cell activation is also mediated by tetraspanins ( Figure 3B4). Tetraspanins function in antigen-presenting cells (APCs) to assist in the presentation of the MHC-peptide complex to T cells. Tetraspanins CD81, CD37, CD82, CD53, and CD63, tether with MHC and associate with stimulators on exosome vesicles which are MHC II-enriched compartments. After the cell membrane is fused with MHC, the exosomes are released and can act as stimuli for T-cell proliferation (28). But there is an additional way in which tetraspanins work with MHC. Tetraspanin microdomains are enriched for MHC II, CD86, and the class II editor human leukocyte antigen in the membrane of APCs. This complex is referred to as the "CDw78 + microdomain" involved in T cell activation (20). Through the above-enumerated regulatory pathways, the TEMs form a web for signal transduction from extracellular stimuli to intracellular-signaling components and ultimately regulate multiple biological processes, including cell activation, proliferation, adhesion, migration, and communication, as well as involvement in pathological conditions, such as autoimmune diseases, metastasis, and viral infection (Table S2 in Supplementary Material).

eXPReSSiON PROFiLeS OF TeTRASPANiNS AND THeiR PARTNeRS ON B CeLLS
Uniquely expressed molecules in certain B cell subsets may serve as markers of the subset or have special function for that particular subpopulation. Systematic analysis of expression of tetraspanins and partners of tetraspanins on B cells may facilitate an understanding of their biological involvement in B cell biology including B cell development and function.

expression of Tetraspanins on the Surface of B Cells
Most tetraspanins are expressed on B cells but differ in abundance in various B cell subsets at different developmental stages (Figure 4). mRNA transcripts of Tspan2-8, 31, 33, CD9, and CD63 are expressed at high levels in mouse progenitor B cells in the bone marrow but at very low levels, except for CD9 and Tspan31, in other B cell subsets (which mainly exist in periphery lymphoid organs). In contradistinction, CD37, CD53, CD82, and Tspan32 all show similar expression patterns of low level expression in mouse pro-B cells but high level in other B cell subpopulations. On tested human B cells (CD38 − naïve B cells, isotype switch memory B cells, and memory B cells), TSPAN3, TSPAN13, CD53, CD37, CD82, CD81, CD63, and TSPAN33 show relatively high levels of mRNA (TPM > 10). TSPAN2, 5, 10, 14, 17, 31, and 32, and UPK1B, ROM1, CD151, and CD9 have detectable mRNA transcripts. But the remaining tetraspanins have no detectable mRNA. In addition, the expression of all tetraspanins except TSPAN19 is detectable in at least one strain of B cell lymphoma cell lines. More expression profiles of tetraspanins can be found in Figure 4 and Table 2.

expression of Tetraspanin Partners on the Surface of B Cells
Affinity capture assays, protein-fragment complementation assays, and two-hybrid tests in the databases of BioGRID (Table  S3 in Supplementary Material) and ingenuity pathway analysis ( Table 1; Table S2 in Supplementary Material) have allowed for the identification of hundreds of tetraspanin interacting partners. The main cell surface partner proteins of tetraspanins are other tetraspanins, integrins, G-protein coupled receptors, and transmembrane receptors like CD19. After removal of the partners expressed in the cytoplasm and the nucleus, there are 93 membrane proteins which potentially interact with extracellular tetraspanins or tetraspanins on the same membrane (Table S3 in Supplementary Material). Some of the tetraspanins which interact with other tetraspanins include CD151, CD37, CD53, CD63, CD81, CD82, CD9, ROM1, TSPAN2, TSPAN3, and TSPAN12 (Table S3 in

FUNCTiONS OF TeTRASPANiNS iN B CeLLS
Tetraspanins modulate cell adhesion, migration, and invasion which are strongly involved in cancer development and progression (29). The association between tetraspanin expression and cancer prognostic is found in many kinds of cancers ( Table 1). In B lymphoma, aberrant expression of CD9, CD81, and CD82 was linked to B-acute lymphoblastic leukemia (30)(31)(32). Increased CD37 expression was found in B cell malignancies and thus CD37 antibodies were developed to deplete malignant B cells for the treatment of chronic lymphocytic leukemia (33). The correlation of tumorigenesis and tetraspanins is discussed in another submission for this topic, so here we focus on the functions of tetraspanins and their partners on normal B cell biology without any further discussion of B cell malignancy. Functions of tetraspanins are summarized in Figure 6 and Table 3.

Act as Markers identifying B Cell Subsets
As discussed above (Figure 4; Table 2), since some tetraspanins are enriched in specific B cell subsets, they may be used  as markers to identify B cell subsets or diagnostic markers for certain diseases. CD9 is reported to be a special shared marker by B-1 cells, MZB cells, and plasma cells in mice. A study demonstrated that CD9 is expressed by plasma cells in response to antigens independent or dependent on T cells, suggesting CD9 is acquired by T cell dependent plasma cells (34). Another study demonstrated that CD9 is a cell surface marker for precursors of human plasma cells in germinal centers. It is based on the evidence that (1) compared to CD9 − cells, CD9 + B cells show higher Blimp-1 but lower Bcl-6 and Pax-5 protein levels, and a faster process of differentiation into plasmablasts in the presence of PC-generating cytokines; (2) expression of CD9 was induced and gradually increased in CD9 − GC-B cells under PC generating condition (35). A recent study showed that murine CD9 is a unique cell surface marker identifying IL-10 competent Bregs and their progenitors (36).

Roles in Cell Activation, Proliferation, Survival, and Development
The CD21/CD19/CD81 complex modulates signal transduction events pivotal for development of B lymphocyte and the normal Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1606 function of humoral immunity. As shown in Figure 1, CD19, a hallmark of B cells, is sustained in its presence on B cells from the earliest pro-B cell stage to plasmablasts during development. CD19 functions as a co receptor of B cells in association with CD21 and CD81. In the complex, CD19 is the signaling molecule bound by Src-family kinases and PI-3 kinase, CD21 binds opsonized foreign antigens, and CD81 is associated with other tetraspanins including CD82, CD63, CD53, and CD9 to enable formation of TEMs (43). CoIP experiments demonstrated association of CD9, CD81, and CD82 with CD19 and digitonin treatment disrupted the CD9/CD19 and CD9/CD81 associations but not the CD81/CD19 association, implying that the association of CD9 with CD19 is through CD81 instead of another molecule. Different proteins including CD19 could be tyrosine phosphorylated which is induced by engagement of CD9, suggesting that CD9 involves B cell activation and differentiation (37). CD81 is one of the key proteins participating in controlling homeostasis of lymphocytes through modulating their proliferation. CD81 KO mice show reduced B1 cells and CD19 expression on B cells although the development of T cells and conventional B cells is normal. Moreover, in CD81 KO mice, the proliferative response of T cells is enhanced following TCR engagement, while proliferation of B cell responding to BCR cross-linking is severely impaired (21). Engagement of CD81 with hepatitis C virus (HCV) envelope protein E2 could protect B cells from apoptosis (56), and induce B cell activation (57,58) and VH hypermutation (59). CD9 appears to function in B cell activation and differentiation based on its expression in specific B cell subsets and its functional interaction with CD19. CD9 is reported as a cell surface marker of B-1 B cells, MZ B cells, and plasma cells, but the development of these B cell subsets as well as the humoral immune responses to antigens appear to be normal when CD9 is knocked out (60). A recent study also confirmed that most of the tested markers expressed on total B cells are not significantly altered when CD9 is mutated. Interestingly, however, the    (21); may interact with a putative ligand on a subpopulation of T cells to signal IL-4 production (41); determines CD19 membrane expression (42); interacts with CD19/CD21 complex and tetraspanins such as CD9, CD53, CD63, and CD82 to enable formation of tetraspanin-enriched microdomains (TEMs) (43); entry factor of hepatitis C virus (44) CD53 Activation, adhesion, development, apoptosis, antibody production Interferes with lymphocyte activation and cell adhesion; a direct genetic target for EBF1 which is a critical transcription factor for early B lymphocyte development, and can be induced by ectopic expression of EBF-1 (45); CD53 mediates PKCβ recruitment from cytosol to TEMs for B cell receptor activation (46). CD53 engagement with antibody against CD53 and Ig promotes activation of resting B cells into the G1 phase and induces Ig production in the presence of T cell supernatant (47)

CD63 Exosome production, virus infection, migration
Suppressor of exosome production and could regulate the exosome-mediated major histocompatibility complex class II-dependent T-cell stimulation (48); sensitized to and controls latent membrane protein 1-mediated NFkB activation for EBV persistence (49); cell migration by affecting the abundance of CXCR4 on the cell surface through IL-21-induced endocytosis and CD63-mediated endosomal recruitment (50)

CD37
Apoptosis, survival, antibody production Regulates the membrane distribution of α(4)β(1) integrin crucial for activating the Akt survival pathways, increases apoptosis of plasma cells in germinal centers (51); initiates a cascade of events leading to apoptosis, counteracts death signals by regulating PI3K-dependent survival (52); promotes IgG1 production while inhibiting IgA immune responses in vivo and protects against the development of IgA nephropathy (53); control suppressor of cytokine signaling 3 (54)

CD82
Protection from cytotoxicity Interferes with the capacity of the MHC-I complex to protect targets from NK-mediated cytotoxicity (55) a Only list the tetraspanins discussed in Section "Functions of tetraspanins on B cells." Tetraspanins on B Cell Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1606 frequency of occurrence of IL10 competent Breg (B10 cells) is increased and CD23 expression is reduced on B10 cells when CD9 is knocked out (36). Moreover, CD9 is reported to facilitate interacting with human follicular dendritic cells through the VLA4/VCAM-1 axis and contribute to the survival of germinal center B cells (38). In addition to its involvement in Ig production, CD53 also contributes to B cell differentiation. A study demonstrated that CD53 is a direct genetic target of EBF-1, a critical transcription factor in early B lymphocyte development. CD53 has functional binding sites for EBF-1 in its promoter elements and can be induced by ectopic expression of EBF-1 (45). CD53 transcripts are enhanced significantly by mitogenic stimulation, implying that CD53 may be involved in the transport of signals important for cell proliferation. Under conditions of serum deprivation, ligation of CD53 in B lymphoma cells triggers an AKT-mediated survival response and prompts a significant reduction in caspase activation and the number of cells that enter apoptosis (61). By using live-cell imaging and gene knockout mice, a recent study demonstrated that CD53 is specifically required for the recruitment of PKCβ (the protein kinase C family member) from cytosol to CD53enriched TEMs on the plasma membrane to activate PKCβ for antigen-dependent BCR activation, suggesting that TEMs act as signaling hotspots (46).
The tetraspanin CD37 has profound roles in B cell proliferation and survival. CD37 regulates the plasma membrane distribution of α(4)β(1) integrins by controlling their mobility and clustering, a necessary step in activating Akt survival pathways. It is reported that the number of IgG-secreting plasma cells is reduced in lymphoid organs when CD37 is knocked out in mice, possibly due to the impaired association of VCAM-1 to the α(4)β(1) integrin for the Akt survival pathway with the corollary of increased apoptosis of plasma cells in germinal centers (51). In a recent study, CD37 knockout in mice can drive B cell lymphoma progression through constitutive activation of the IL6 pathway by losing the control of suppressor of cytokine signaling 3 (54). Although CD37 is crucial for B cells to survive and provide long lasting immune protection, another study reported that CD37 may trigger a cascade of events resulting in apoptosis when it is tyrosine phosphorylated and binds with signaling factors. The study also found that CD37 mediates SHP1-dependent death via its N-terminal domain, whereas it antagonizes death signals through the C-terminal domain by mediating PI3Kdependent survival (52).
CD82 associates with MHC-I at the cell surface of B cells and could interfere with the capacity of the MHC-I complex to protect targets from NK-mediated cytotoxicity (55). CD63 is reported as a suppressor of exosome production and could regulate exosome-mediated MHC II-dependent T-cell stimulation (48).

Roles in Antibody Production
In addition to its role in B cell proliferation and selection of IgG + plasma cells, CD37 promotes IgG1 production while inhibiting IgA immune responses in vivo. CD37 deficiency causes a reduction of serum IgG1 levels and alters B cell responses to T cell-dependent antigen under suboptimal costimulatory conditions (62). Besides the reduction in serum IgG1 levels, CD37 deficiency in B cells causes high levels of IL-6 and is directly responsible for the increased IgA + plasma cell numbers and IgA production levels in CD37 −/− mice. CD37 −/− mice are better protected from infection by Candida albicans than WT mice due to the increased C. albicans-specific IgA antibody levels. Neutralization of IL-6 in vivo could reverse the enhanced IgA response in CD37 −/− mice (63). Therefore, it is not surprising to find that CD37 protects against the development of IgA nephropathy by controlling the formation and deposit of IgAantigen complexes in the glomerulus (53).
The absence of CD81 on murine B cells causes a defect of antibody responses to T cell-dependent protein antigens and reduces the production of IL-4 that is specific to antigens in both spleens and lymph nodes. A putative ligand on a subpopulation of B and T cells may interact with CD81 to signal IL-4 production (41). The function of CD81 was confirmed in a patient carrying a homozygous mutation of the CD81 gene which caused the syndrome of antibody deficiency by disrupting the CD19 complex in B cells and impairing BCR activation although the CD19 alleles in the patient are normal. Otherwise, the patient had neither overt T cell subset nor functional defects, similar to CD19-deficient patients. Further study revealed that CD19 membrane expression critically depends on CD81 and no cell surface CD19 could be observed on B cells from the patient who had the mutated CD81 (42).
Besides the above proteins, CD53 also plays an important role in activation and differentiation of B cells. CD53 engagement with both the MEM-53 antibody against CD53 and a polyclonal anti-mouse immunoglobulin promotes B cell activation from resting status into the G1 phase, and induces Ig production when treated with T cell supernatant (47).

immune Suppression
A study has shown that CD9 is a unique cell surface marker for murine B10 cells and their progenitor cells. Moreover, CD9 + B cells are capable of inhibiting contact hypersensitivity mediated by Th1 cells in vivo. Further ex vivo assays demonstrated that CD9 is involved in cross-talk between B cells and T cells, which is required for IL10 + B cells to suppress proliferation of T cells (36). Another study also indicated that IL-10 + Bregs are enriched in a CD9 + B cell subset and their homeostasis is altered by induced allergic asthma. Adoptive transfer of CD9 + B cells in asthmatic mice normalizes lung function in an IL-10dependent manner via inhibiting inflammation driven by Th2 and Th17 cells (39).

Roles in virus infection
Both CD9 and CD63 were identified and found to be transcribed by IgM + cells in different tissues of rainbow trout (Oncorhynchus mykiss). And the abundance of CD9 transcripts decreased significantly in IgM + splenocytes when the cells were exposed in vitro to viral hemorrhagic septicemia virus (64). Overexpression of CD9 caused a significantly higher yield of extracellular vesicles and improved the speed and efficiency of lentiviral gene delivery into T and B cells with the lentivirus produced in the CD9 high cells, although the virus titers were not increased. The study indicates an important role for CD9 in membrane fusion, virus infection, and information transfer mediated by extracellular microvesicles (40). Viral oncogene latent membrane protein 1 (LMP1) accumulates within intraluminal vesicles to avoid degradation and thus constitutively activates NF-κB which is important for EBV persistence in B cells. CD63 associates with LMP1 and facilitates the inclusion of LMP1 into vesicles lacking MHC II. Preclusion of LMP1 assembly within CD63-enriched domains by C-terminal modifications of LMP1 leads to NF-κB overstimulation. Interference through shRNAs against CD63 causes redistribution of LMP1 and leads to a dramatic increase in LMP1-induced NF-κB activity, indicating that CD63 is sensitized to and controls LMP1-mediated NF-κB activation (49).
CD81 plays important roles in HCV infection by acting as a HCV entry factor (65), promoting HCV RNA replication (66), and reducing HCV-induced immune responses (44). B cells expressing CD81 can be infected by HCV and serve as reservoirs for chronic HCV infection (67).

Cell Migration, Adhesion
CD63 plays important roles in cell migration as it can affect the abundance of CXCR4 on the cell surface through IL-21-stimulated endocytosis and endosomal recruitment. Restimulation of activated B cells with T cell-produced IL-21 accelerates CXCR4 internalization by inducing endocytosisrelated GRK6 expression. The level of CD63 is strikingly elevated in activated Bcl6-deficient B cells and downregulation of CD63 mRNA with siRNAs upregulates CXCR4 expression on the B cells. Activated B cells treated with Bcl6 inhibitor have a similar phenotype to Bcl6-deficient B cells: increased CD63 mRNA expression and downregulated CXCR4 expression (50). It is reported that CD53 plays an important role in homotypic cell aggregation of lymphocytes and may interfere with lymphocyte activation and cell adhesion. HI29, an anti-CD53 monoclonal antibody, was able to induce homotypic cell aggregation in a B cell strain from a leukocyte adhesion deficiency patient. Moreover, pre-incubation with MEM53, another antibody against CD53, can block such aggregation but anti-CD44 or anti-CD49d mAbs have no blocking effects. Tetraspanins also interact with integrins which function within the area of cellular motility. Ectopic expression of CD9 has been reported to enhance B cell migration via interacting with integrins α6β1 and α4β1 (23). α4β1 on B cells can also be associated with CD81 (68).

FUNCTiONS OF TeTRASPANiN PARTNeRS eXPReSSeD ON B CeLLS
The partners of tetraspanins have multiple functions in B cellsincluding regulation of B cell activation, survival, development, antibody production, virus infection, and signal transductionthrough mechanisms which may not be correlated with the interaction between tetraspanins and the partners. More details can be found in Table 4.

THeRAPY STRATeGieS FOR iMMUNe DiSeASeS CORReLATeD wiTH TeTRASPANiNS AND THeiR PARTNeRS
Most studies on employing tetraspanins and their partners as therapy target of diseases involve cancer treatments, a subject outside the scope of this review. For other diseases, there are some strategies using tetraspanins and their partners on B cells as therapy targets, as we explain below.
Depletion of B Cell Subsets, Blockade of Receptors or Crosslinking with Antibodies Against Certain Tetraspanins or Partners CD21 can be used as a target for depletion of EBV positive B cells as it is a receptor for EBV on B cells. CD19 is a hallmark of B cells and could be used as a target for B cell depletion in the treatment of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus (SLE). There is a phase I clinical trial (Identifier: NCT00639834, ClinicalTrials.gov) using anti-CD19 antibody MDX-1342 together with methotrexate for the treatment of patients with rheumatoid arthritis.
CD81 is an entry factor for HCV infection. Monoclonal antibodies with high affinity to CD81 are generated for prevention of HCV infection (108).
TNFRSF17/BCMA is preferentially expressed in CD180 − B cells which produce autoantibodies and are significantly increased in SLE (104,105,109). TNFRSF17/BCMA and CD180 − B cell subsets would be ideal targets for SLE treatment.
CD44 engagement could control CD40L-mediated polyclonal B cell activation (88). Cross-linking of CD53 with antibodies against CD53 promotes activation of resting B cells, speeds up the entrance into the G1 phase of cell cycle, and induces Ig production during the incubation with T cell supernatant (47).

Reduction of Protein Abundance with shRNAs or siRNAs Against Certain Tetraspanins or Partners
Interference through shRNAs against CD63 causes redistribution of LMP1, leads to a dramatic increase in LMP1-induced NF-κB activity, and would benefit treatment of EBV infection (49).

Overexpression or Delivery of Certain Tetraspanins or Partners in B Cells
CD9 expression increases exosome production and promotes lentivirus infection (40), thus CD9 could be overexpressed in the engineered cells producing therapeutic exosomes to enhance the yield of exosomes and the delivery efficiency of exosomes.
interference of Tetraspanins or Partners with Small Molecules, inhibitors, or Stimulators of Diseases ADAM10 improves IgE production via its sheddase activity on CD23, an IgE receptor with low affinity (70). Adam10 increases in the B cells of allergic patients and Th2 prone mice (71) and  (37,73,74); pivotal for Akt activation that is mediated by BCR (75); intensifies Src-family PTK activation following BCR ligation (76); important for recruitment of Vav, Grb2, PI3K, phospholipase Cγ2, and c-Abl, or SHPI and SHIP phosphatases (77) CD1d CD82 Regulates interaction between activated T cells and B cells which is crucial to B cell proliferation and antibody production (78); mediates antigen presentation and augments antibody responses (79); CD1d knockout in mice impairs resistance to Borrelia burgdorferi infection due to impaired antibody production (80)